ADMEDES IDEAS. EXPERTISE. PASSION.	MANUFACTURER STATEMENT	

MANUFACTURER STATEMENT EU MDR 2017/745 DECLARATION

PHTHALATES, NANOMATERIALS, SUBSTANCES CARCINOGENIC, MUTAGENIC OR TOXIC TO REPRODUCTION

The ADMEDES Group (hereinafter referred to as “ADMEDES”) hereby declares that, based on the information available regarding the materials and manufacturing processes relevant to the supplied products, components, parts and semi-finished products manufactured by ADMEDES are not intentionally manufactured using or formulated to contain phthalates, substances classified as carcinogenic, mutagenic or toxic to reproduction (CMR Category 1A or 1B), or substances identified as endocrine disruptors, above the applicable regulatory thresholds.

Furthermore, nanomaterials, as defined in Regulation (EU) 2017/745, are not intentionally incorporated into the supplied products, nor are they intentionally used in manufacturing processes in a manner that would result in their incorporation into the supplied products.

This declaration is made with reference to Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 (EU MDR), Annex I, Chapter II, Sections 10.4 and 10.6.

The assessment refers to the following applicable regulatory requirements:

• **Regulation (EC) No 1272/2008 (CLP)** on the classification, labelling and packaging of substances and mixtures, including the applicable harmonised classifications listed in Annex VI, as amended by the relevant Adaptations to Technical Progress (ATPs).

- ATP 17 (shall apply from 17 December 2022),
- ATP 18 (shall apply from 1 December 2023),
- ATP 21 (shall apply from 1 September 2025),
- ATP 22 (shall apply from 1 May 2026),
- ATP 23 (shall apply from 1 February 2027),

• **Regulation (EC) No 1907/2006 (REACH)** – Candidate list of substances of very high concern (SVHC) published in accordance with Article 59(10), as last updated on February 04, 2026.

• **Regulation (EU) No 528/2012** on biocidal products (BPR) – for substances identified as endocrine disruptors for human health, as published on 17 July 2025.

This declaration reflects the current regulatory status as of the date below.

Signed in Pforzheim
Date: October 16, 2026

For and on behalf of ADMEDES
i.V. Andreas Butz

Bereichsleiter Prozessbetreuung
Vice President Process Engineering

ADMEDES IDEAS. EXPERTISE. PASSION.
ADMEDES GmbH
a company of the G.RAU Group
Rastatter Str. 15, 75179 Pforzheim, Germany
+49 7231 92231-261, +49 162 2621 761
abutz@admedes.com, www.admedes.com

This information is believed to be accurate and refers to the laws, regulations and products at the date of issue. However, ADMEDES makes no express or implied representations or warranties with respect to the information contained herein. It is the responsibility of our customers to determine that their products are safe, lawful, and technically suitable for their applications. Because of possible changes in the laws and regulations, we cannot guarantee that the status of this article will remain unchanged.